June 1st 2023
Apremilast is being examined for the treatment of psoriatic arthritis.
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Clinical Consultations: Individualizing Management of Uveitic Macular Edema - Clinical Updates in Treatment Options
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application
April 26th 2021Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.
FDA approves guselkumab for psoriatic arthritis
July 16th 2020Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) following positive phase 3 results from two trials investigating the safety and efficacy of the drug.